Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Immuneering (NASDAQ:IMRX – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently issued reports on IMRX. Mizuho set a $11.00 price objective on shares of Immuneering in a research note on Thursday, October 29th. HC Wainwright reissued a “buy” rating on shares of Immuneering in a research report on Friday, October 30th. Needham & Company LLC boosted their price objective on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a report on Monday, September 21st. Finally, UBS Group set a $14.00 price objective on Immuneering in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

Read Our Latest Stock Analysis on IMRX

Immuneering Price Performance

Shares of IMRX stock opened at $3.68 on Friday. The company has a market capitalization of $238.32 million, a PE ratio of -3.57 and a beta of 0.49. Immuneering has a 12 month low of $3.35 and a 12 month high of $8.48. The firm’s 50-day moving average is $4.12 and its two-hundred day moving average is $4.77.

Immuneering (NASDAQ:IMRX – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). Sell-side analysts forecast that Immuneering will post -1.19 EPS for the current year.

Institutional Trading of Immuneering

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aberdeen Group plc bought a new stake in shares of Immuneering in the 3rd quarter valued at about $3,214,000. PVG Asset Management Corp purchased a new stake in Immuneering during the 1st quarter valued at about $773,000. Weiss Asset Management LP purchased a new stake in Immuneering during the 1st quarter valued at approximately $464,000. Corient Private Wealth LP acquired a new stake in shares of Immuneering in the second quarter worth $385,000. Finally, Hsbc Holdings PLC bought a new position in Immuneering in the 1st quarter worth approximately $198,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

(Get Free Report)

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.

Featured Articles